Plain-English translation of NCT03975231 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether two medications called and , given together with radiation therapy, can effectively treat anaplastic thyroid cancer — a rare but very aggressive form of thyroid cancer. These two medications work by targeting a specific genetic change (called a BRAF mutation) that is found in your cancer cells. The main goal is to find the safest and most effective dose of these medications to give alongside radiation.
Anaplastic thyroid cancer spreads very quickly and is difficult to treat with standard approaches. Researchers have discovered that targeting the BRAF mutation in these cancers may help slow or stop their growth. This trial is designed to see if combining this new medication strategy with radiation can give patients better outcomes.
You likely qualify if…
You likely don't qualify if…
You will first take the two medications by mouth for 1–4 weeks to see how your cancer responds (this is called the induction phase). If your cancer is operable, you may have surgery. You will then take the same medications for about 6.5 weeks while receiving daily radiation therapy on weekdays. After radiation ends, you will continue taking the medications for 4 more weeks, and possibly longer if there is remaining disease. Throughout the trial, you'll have regular blood tests and scans to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States